Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 80.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 736,197 shares of the biopharmaceutical company's stock after purchasing an additional 327,936 shares during the period. JPMorgan Chase & Co. owned 0.62% of Catalyst Pharmaceuticals worth $15,364,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. FMR LLC grew its holdings in shares of Catalyst Pharmaceuticals by 24.3% during the third quarter. FMR LLC now owns 98,580 shares of the biopharmaceutical company's stock worth $1,960,000 after buying an additional 19,270 shares during the last quarter. Wellington Management Group LLP acquired a new stake in Catalyst Pharmaceuticals during the 3rd quarter worth approximately $1,185,000. Jane Street Group LLC grew its stake in shares of Catalyst Pharmaceuticals by 245.4% in the 3rd quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company's stock valued at $7,990,000 after purchasing an additional 285,564 shares during the last quarter. XTX Topco Ltd increased its holdings in shares of Catalyst Pharmaceuticals by 73.3% in the third quarter. XTX Topco Ltd now owns 19,294 shares of the biopharmaceutical company's stock valued at $384,000 after purchasing an additional 8,160 shares during the period. Finally, Barclays PLC raised its stake in shares of Catalyst Pharmaceuticals by 129.4% during the third quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company's stock worth $4,939,000 after purchasing an additional 140,129 shares during the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX traded up $0.31 during mid-day trading on Thursday, hitting $22.50. 154,551 shares of the company's stock traded hands, compared to its average volume of 1,138,631. The firm's 50 day simple moving average is $22.61 and its 200 day simple moving average is $22.05. The company has a market cap of $2.73 billion, a PE ratio of 19.12, a price-to-earnings-growth ratio of 3.31 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.47 and a 1 year high of $26.16.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. HC Wainwright reiterated a "buy" rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Robert W. Baird raised their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, March 3rd. StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Finally, Stephens reissued an "overweight" rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $32.29.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares of the company's stock, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gary Ingenito sold 44,904 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. Insiders own 11.00% of the company's stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.